What Did HHS Announce on 28 October 2026 About Compounding Six Peptides?

What Did HHS Announce on 28 October 2026?

On Wednesday 28 October 2026 the US Department of Health and Human Services announced an enforcement-discretion policy covering six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500.[1][2][3][5] Under the policy, HHS says it will not take action against state-licensed pharmacies, federal facilities or licensed physicians that compound those substances, provided they meet stated conditions.[3][4] Outlets differ on framing: some describe a draft policy and others a final one, and one report cites docket HHS-OASH-2026-0496. Readers should confirm the status in the Federal Register notice rather than rely on a summary.[4]

This follows the draft "interim access policy" that reached the White House Office of Management and Budget on 14 October, whose text had not been published when we covered it in our OMB review guide. Our regulated peptide marketplace timeline tracks the sequence of events.

What Conditions Are Reported?

Press accounts describe conditions attached to the discretion. One report counts ten. We could not retrieve the primary text from our publishing environment, so the list below is limited to items the reporting mentions.[2][3]

Is Enforcement Discretion the Same as Approval or a Bulks-List Listing?

No. The three mechanisms are legally distinct, and the reporting presents this policy as a bridge while formal rulemaking proceeds. Notice-and-comment rulemaking is reported to take 12 to 24 months.[3] Our FDA peptide reclassification guide covers how the pathways interact.

How Does It Relate to the July Advisory Committee Vote?

In July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to support adding these substances to the 503A list; see our PCAC vote outcome guide. Advisory votes are non-binding. Reporting notes that FDA officials said agency scientific staff had significant safety concerns and would not support a regulation deeming the peptides safe.[3] An Associated Press report published on 28 October said FDA scientists opposed the effort to ease access, and the consumer group Public Citizen criticised the move.[1] Those are third-party characterisations. HHS describes the policy as pairing access with safety conditions.

What Should Researchers Watch Next?

Four open questions will determine how durable the policy is. First, the status of the document itself: whether the Federal Register text matches the press summaries, and whether it is a draft open to comment or a final statement.[4] Second, the rulemaking track: a proposed rule to add the six substances to the 503A bulks list would start a public comment period, and the length of that process is the practical limit on any interim policy.[3] Third, legal and political challenge: because enforcement discretion is not a statute, it can be narrowed or withdrawn by this or a later administration, and critics including FDA scientists have already voiced opposition.[1] Fourth, state boards of pharmacy, which license compounding pharmacies and may adopt their own positions (our inference; not stated in the reporting).

For context on the wider regulatory picture, our week-in-review for 18-24 October 2026 records the position immediately before this announcement. Nothing here changes the research-use status of any compound, or the fact that none of the six has a marketing authorisation from the MHRA or the FDA.

What Does This Mean for Researchers?

It is a US pharmacy-compounding story, and it does not alter what the underlying evidence shows. The published literature on these peptides remains largely preclinical, and our injectable peptide evidence review summarises where it stands. For researchers, the practical points are documentation and provenance: certificates of analysis, HPLC and mass-spectrometry identity data, and batch traceability. Keep three categories apart: licensed pharmaceutical development (for example retatrutide, an investigational Lilly compound with no marketing authorisation anywhere), US regulatory process, and research-use compounds handled in vitro. Reagent pages for the named peptides: BPC-157, TB-500, KPV, MOTS-c and Semax.

Does a US Policy Change UK Research-Reagent Rules?

No. The 503A framework governs US pharmacies preparing compounded drugs. UK supply of research reagents sits under separate law and MHRA guidance; see are research peptides legal in the UK? A US enforcement choice does not make any product a UK medicine or change a reagent's intended use.

Compounds are supplied by Velox Peptides as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions